Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 104926, 7 pages
http://dx.doi.org/10.1155/2011/104926
Review Article

Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Received 4 July 2011; Accepted 18 August 2011

Academic Editor: Hans Wilhelm Nijman

Copyright © 2011 Norimitsu Kadowaki and Toshio Kitawaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Ishikawa, S. Yoshida, Y. Saito et al., “Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region,” Nature Biotechnology, vol. 25, no. 11, pp. 1315–1321, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. Menzin, K. Lang, C. C. Earle, D. Kerney, and R. Mallick, “The outcomes and costs of acute myeloid leukemia among the elderly,” Archives of Internal Medicine, vol. 162, no. 14, pp. 1597–1603, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Ohminami, M. Yasukawa, and S. Fujita, “HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T- lymphocyte clone specific for WT1 peptide,” Blood, vol. 95, no. 1, pp. 286–293, 2000. View at Google Scholar · View at Scopus
  4. L. Gao, I. Bellantuono, A. Elsässer et al., “Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1,” Blood, vol. 95, no. 7, pp. 2198–2203, 2000. View at Google Scholar · View at Scopus
  5. K. Inoue, H. Tamaki, H. Ogawa et al., “Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells,” Blood, vol. 91, no. 8, pp. 2969–2976, 1998. View at Google Scholar · View at Scopus
  6. A. Gaiger, V. Reese, M. L. Disis, and M. A. Cheever, “Immunity to WT1 in the animal model and in patients with acute myeloid leukemia,” Blood, vol. 96, no. 4, pp. 1480–1489, 2000. View at Google Scholar · View at Scopus
  7. O. A. Elisseeva, Y. Oka, A. Tsuboi et al., “Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies,” Blood, vol. 99, no. 9, pp. 3272–3279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Scheibenbogen, A. Letsch, E. Thiel et al., “CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia,” Blood, vol. 100, no. 6, pp. 2132–2137, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. K. Rezvani, M. Grube, J. M. Brenchley et al., “Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation,” Blood, vol. 102, no. 8, pp. 2892–2900, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. K. Rezvani, A. S. M. Yong, B. N. Savani et al., “Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia,” Blood, vol. 110, no. 6, pp. 1924–1932, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. J. Molldrem, S. Dermime, K. Parker et al., “Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells,” Blood, vol. 88, no. 7, pp. 2450–2457, 1996. View at Google Scholar · View at Scopus
  12. J. J. Molldrem, P. P. Lee, C. Wang et al., “Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia,” Nature Medicine, vol. 6, no. 9, pp. 1018–1023, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. Greiner, L. Li, M. Ringhoffer et al., “Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia,” Blood, vol. 106, no. 3, pp. 938–945, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. Arai, M. Yasukawa, H. Ohminami, M. Kakimoto, A. Hasegawa, and S. Fujita, “Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes,” Blood, vol. 97, no. 9, pp. 2903–2907, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Morita, Y. Heike, M. Kawakami et al., “Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation,” International Journal of Cancer, vol. 119, no. 6, pp. 1360–1367, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. K. Rezvani, A. S. M. Yong, A. Tawab et al., “Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia,” Blood, vol. 113, no. 10, pp. 2245–2255, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. T. Ochi, H. Fujiwara, K. Suemori et al., “Aurora-A kinase: a novel target of cellular immunotherapy for leukemia,” Blood, vol. 113, no. 1, pp. 66–74, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Y. Saito, H. Kitamura, A. Hijikata et al., “Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells,” Science Translational Medicine, vol. 2, no. 17, pp. 17–ra9, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. Y. Oka, A. Tsuboi, T. Taguchi et al., “Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 38, pp. 13885–13890, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. Y. Oka, A. Tsuboi, M. Murakami et al., “Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis,” International Journal of Hematology, vol. 78, no. 1, pp. 56–61, 2003. View at Google Scholar · View at Scopus
  21. U. Keilholz, A. Letsch, A. Busse et al., “A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS,” Blood, vol. 113, no. 26, pp. 6541–6548, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. K. Rezvani, A. S. M. Yong, S. Mielke et al., “Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies,” Blood, vol. 111, no. 1, pp. 236–242, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. P. G. Maslak, T. Dao, L. M. Krug et al., “Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia,” Blood, vol. 116, no. 2, pp. 171–179, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. J. May, T. Dao, J. Pinilla-Ibarz et al., “Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4 + and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells,” Clinical Cancer Research, vol. 13, no. 15, pp. 4547–4555, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. C. J. M. Melief and S. H. Van Der Burg, “Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines,” Nature Reviews Cancer, vol. 8, no. 5, pp. 351–360, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. M. S. Bijker, S. J. F. van den Eeden, K. L. Franken, C. J. M. Melief, S. H. van der Burg, and R. Offringa, “Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation,” European Journal of Immunology, vol. 38, no. 4, pp. 1033–1042, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. Schmitt, A. Schmitt, M. T. Rojewski et al., “RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses,” Blood, vol. 111, no. 3, pp. 1357–1365, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. I. M. Borrello, H. I. Levitsky, W. Stock et al., “Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML),” Blood, vol. 114, no. 9, pp. 1736–1745, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. V. T. Ho, M. Vanneman, H. Kim et al., “Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15825–15830, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. S. I. Fujii, K. Shimizu, K. Fujimoto et al., “Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells,” Leukemia and Lymphoma, vol. 42, no. 3, pp. 357–369, 2001. View at Google Scholar · View at Scopus
  31. L. Li, K. Giannopoulos, P. Reinhardt et al., “Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts,” International Journal of Oncology, vol. 28, no. 4, pp. 855–861, 2006. View at Google Scholar · View at Scopus
  32. H. Roddie, M. Klammer, C. Thomas et al., “Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia,” The British Journal of Haematology, vol. 133, no. 2, pp. 152–157, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Draube, M. Beyer, and J. Wolf, “Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells,” European Journal of Haematology, vol. 81, no. 4, pp. 281–288, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. J. J. Lee, H. Kook, M. S. Park et al., “Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation,” Journal of Clinical Apheresis, vol. 19, no. 2, pp. 66–70, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. V. F. Van Tendeloo, A. Van De Veldea, A. Van Driesschea et al., “Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 31, pp. 13824–13829, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. T. Kitawaki, N. Kadowaki, K. Fukunaga et al., “Cross-priming of CD8+ T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia,” Experimental Hematology, vol. 39, no. 4, pp. 424.e2–433.e2, 2011. View at Google Scholar
  37. T. Kitawaki, N. Kadowaki, K. Fukunaga et al., “A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate,” The British Journal of Haematology, vol. 153, no. 6, pp. 796–799, 2011. View at Google Scholar
  38. M. Theobald, J. Biggs, J. Hernández, J. Lustgarten, C. Labadie, and L. A. Sherman, “Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes,” Journal of Experimental Medicine, vol. 185, no. 5, pp. 833–841, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. O. J. Finn, “Molecular origins of cancer: cancer immunology,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2704–2715, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. S. A. Rosenberg, J. R. Yannelli, J. C. Yang et al., “Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2,” Journal of the National Cancer Institute, vol. 86, no. 15, pp. 1159–1166, 1994. View at Google Scholar · View at Scopus
  41. R. A. Morgan, M. E. Dudley, J. R. Wunderlich et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science, vol. 314, no. 5796, pp. 126–129, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. L. A. Johnson, R. A. Morgan, M. E. Dudley et al., “Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen,” Blood, vol. 114, no. 3, pp. 535–546, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. R. Parkhurst, J. C. Yang, R. C. Langan et al., “T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis,” Molecular Therapy, vol. 19, no. 3, pp. 620–226, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. T. Tsuji, M. Yasukawa, J. Matsuzaki et al., “Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes,” Blood, vol. 106, no. 2, pp. 470–476, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. A. Xue, L. Gao, D. Hart et al., “Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells,” Blood, vol. 106, no. 9, pp. 3062–3067, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. S. A. Xue, L. Gao, S. Thomas et al., “Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice,” Haematologica, vol. 95, no. 1, pp. 126–134, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. T. Ochi, H. Fujiwara, S. Okamoto et al., “Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked anti-leukemia reactivity and safety,” Blood, vol. 118, no. 6, pp. 1495–1503, 2011. View at Google Scholar
  48. T. M. Schmitt, G. B. Ragnarsson, and P. D. Greenberg, “T cell receptor gene therapy for cancer,” Human Gene Therapy, vol. 20, no. 11, pp. 1240–1248, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. G. M. Bendle, C. Linnemann, A. I. Hooijkaas et al., “Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy,” Nature Medicine, vol. 16, no. 5, pp. 565–570, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. S. Okamoto, J. Mineno, H. Ikeda et al., “Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR,” Cancer Research, vol. 69, no. 23, pp. 9003–9011, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. J. N. Kochenderfer, W. H. Wilson, J. E. Janik et al., “Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19,” Blood, vol. 116, no. 20, pp. 4099–4102, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, “Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2,” Molecular Therapy, vol. 18, no. 4, pp. 843–851, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain, “Treatment of chronic lymphocytic leukemia with genetically targeted autologous t cells: case report of an unforeseen adverse event in a phase i clinical trial,” Molecular Therapy, vol. 18, no. 4, pp. 666–668, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. S. Peinert, H. M. Prince, P. M. Guru et al., “Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis y antigen,” Gene Therapy, vol. 17, no. 5, pp. 678–686, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. G. Q. Phan, J. C. Yang, R. M. Sherry et al., “Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8372–8377, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. J. R. Brahmer, C. G. Drake, I. Wollner et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167–3175, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato, “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12293–12297, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. T. Ishida, T. Ishii, A. Inagaki et al., “Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege,” Cancer Research, vol. 66, no. 11, pp. 5716–5722, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. J. Shimizu, S. Yamazaki, and S. Sakaguchi, “Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity,” Journal of Immunology, vol. 163, no. 10, pp. 5211–5218, 1999. View at Google Scholar · View at Scopus
  61. M. A. Morse, A. C. Hobeika, T. Osada et al., “Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines,” Blood, vol. 112, no. 3, pp. 610–618, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. M. Almstedt, N. Blagitko-Dorfs, J. Duque-Afonso et al., “The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells,” Leukemia Research, vol. 34, no. 7, pp. 899–905, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. O. Goodyear, A. Agathanggelou, I. Novitzky-Basso et al., “Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia,” Blood, vol. 116, no. 11, pp. 1908–1918, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus